Lithuanian digital health startup Self.co raises €2.56M to advance allergy and food intolerance testing technology

Self.co, a Vilnius-based digital health company helping people better understand and manage allergies and food intolerances, has raised €2.56 million in a combined grant and venture funding round. The company shared the news with AIN.

Investment details 

The funding round of €1.2 million was led by Iron Wolf Capital, with participation from Coinvest, NGL Ventures, and several angel investors. Self.co received a €1.36 million grant from Innovation Agency Lithuania to improve its testing technology.

• Iron Wolf Capital is a venture capital firm, based in Vilnius and London, focused on early-stage investments, primarily in the Baltic region. 
• The fund supports startups across various technology sectors, aiming to help founders scale their businesses regionally and internationally

The pooled funds will now support expansion into new markets and further development of Self.co’s proprietary testing technology and long-term management tools.

About Self.co

• Self.co, founded in 2015 by Gintautas Gylys, is a digital health and diagnostics company helping people understand allergy-like symptoms through molecular testing and expert guidance. 
• The company controls its entire testing process, from technology development to lab analysis. Its proprietary microarray tests analyse 98 allergens and 220 food sensitivities from a simple blood sample taken at home or in partner clinics. 
• Beyond testing, Self.co provides users with personalized avoidance plans and, when needed, supplements or treatments, empowering thousands to properly diagnose allergy-like symptoms and live healthier livestock.

Read more: Iron Wolf Capital launched €100m Baltic deep tech and AI fund to back early-stage startups